Endoscopic findings can predict the efficacy of leukocytapheresis for steroid-naive patients with moderately active ulcerative colitis

Umehara, Yasushi; Kudo, Masatoshi; Kawasaki, Masanori; Watson, Alastair J. M.
September 2008
World Journal of Gastroenterology;9/14/2008, Vol. 14 Issue 34, p5316
Academic Journal
AIM: To investigate the therapeutic usefulness of leukocytapheresis (LCAP; Cellsoba) in steroid-naive patients with moderately active ulcerative colitis (UC). METHODS: Eighteen steroid-naive patients with moderately active UC received one LCAP session every week for five consecutive weeks. RESULTS: The remission rate 8 weeks after the last LCAP session was 61.1% (11/18). All three patients with deep ulcers showed worsening after LCAP. For the remaining 15 patients, who had erosions or geographic ulcers, the average clinical activity index (CAI) score dropped significantly from 9.4 to 3.8 eight weeks after the last LCAP session (t = 4.89, P = 0.001). The average C-reactive protein (CRP) levels before and after LCAP were 1.2 mg/dL and 1.0 mg/dL, respectively. Of the patients with erosions, geographic ulcers, and deep ulcers, 100% (9/9), 33.3% (2/6), and 0% (0/3) were in remission 8 weeks after the last LCAP session, respectively (χ² = 7.65, P < 0.005). Forty-eight weeks after the last LCAP session, the remission rates for patients with erosions and geographic ulcers were 44.4% (4/9) and 16.7% (1/6), respectively. Only one patient suffered a mild adverse event after LCAP (nausea). CONCLUSION: LCAP is a useful and safe therapy for steroid-naive UC patients with moderate disease activity. Moreover, the efficacy of the treatment can be predicted on the basis of endoscopic findings.


Related Articles

  • Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis.  // Inflammatory Bowel Disease Monitor;2012, Vol. 13 Issue 2, p70 

    Sandborn et al. have published a dose-ranging, double-blind, randomized, placebo-controlled trial of tofacitinib (an oral Janus kinase inhibitor) in 194 adult patients with moderate-to-severe ulcerative colitis. The primary endpoint (clinical response rate at 8 weeks) was statistically higher...

  • Decreased Plasma Histidine Level Predicts Risk of Relapse in Patients with Ulcerative Colitis in Remission. Hisamatsu, Tadakazu; Ono, Nobukazu; Imaizumi, Akira; Mori, Maiko; Suzuki, Hiroaki; Uo, Michihide; Hashimoto, Masaki; Naganuma, Makoto; Matsuoka, Katsuyoshi; Mizuno, Shinta; Kitazume, Mina T.; Yajima, Tomoharu; Ogata, Haruhiko; Iwao, Yasushi; Hibi, Toshifumi; Kanai, Takanori // PLoS ONE;10/16/2015, Vol. 10 Issue 10, p1 

    Ulcerative colitis (UC) is characterized by chronic intestinal inflammation. Patients with UC have repeated remission and relapse. Clinical biomarkers that can predict relapse in UC patients in remission have not been identified. To facilitate the prediction of relapse of UC, we investigated the...

  • High-Definition Chromoendoscopy Improves Dysplasia Detection in Ulcerative Colitis. Lederman, Lynne; Subramanian, Venkat // MD Conference Express;Jul2015, Vol. 15 Issue 14, p15 

    A small single-center trial showed that high-definition chromoendoscopy improves detection of dysplastic lesions in patients with long-standing ulcerative colitis during screening endoscopy as compared with high-definition white light endoscopy. These results will be confirmed in a larger UK...

  • Endomicroscopy for Assessing Mucosal Healing in Patients with Ulcerative Colitis. Gheorghe, Cristian; Cotruta, Bogdan; Iacob, Razvan; Becheanu, Gabriel; Dumbrava, Mona; Gheorghe, Liana // Journal of Gastrointestinal & Liver Diseases;Dec2011, Vol. 20 Issue 4, p423 

    The assessment of tissue healing has emerged as an important treatment goal in patients with inflammatory bowel disease. In patients with ulcerative colitis (UC), mucosal healing may represent the ultimate therapeutic goal due to the fact that the inflammation is limited to the mucosal layer....

  • Relationship between non-adherence to aminosalicylate medication and the risk of clinical relapse among Japanese patients with ulcerative colitis in clinical remission: a prospective cohort study. Kawakami, Aki; Tanaka, Makoto; Nishigaki, Masakazu; Naganuma, Makoto; Iwao, Yasushi; Hibi, Toshifumi; Sanada, Hiromi; Yamamoto-Mitani, Noriko; Kazuma, Keiko // Journal of Gastroenterology;Sep2013, Vol. 48 Issue 9, p1006 

    Background: Thirty to forty-five percent of ulcerative colitis (UC) patients show non-adherence to aminosalicylates, and non-adherence has been reported to increase the risk of clinical relapse. Because Japan differs from Western countries in terms of health care and drugs administered,...

  • Fecal Calprotectin and the Clinical Activity Index Are Both Useful to Monitor Medical Treatment in Patients with Ulcerative Colitis. Burri, Emanuel; Beglinger, Christoph; Felten, Stefanie; Lehmann, Frank // Digestive Diseases & Sciences;Feb2015, Vol. 60 Issue 2, p485 

    Background: Non-invasive monitoring of inflammatory bowel disease is an unmet clinical need as patients in clinical remission may have residual mucosal inflammation preceding clinical relapse. Aims: We aimed to assess the value of fecal calprotectin and standardized clinical activity scoring to...

  • Response to First Intravenous Steroid Therapy Determines the Subsequent Risk of Colectomy in Ulcerative Colitis Patients. Molnár, Tamás; Farkas, Klaudia; Nyári, Tibor; Szepes, Zoltán; Nagy, Ferenc; Wittmann, Tibor // Journal of Gastrointestinal & Liver Diseases;Dec2011, Vol. 20 Issue 4, p359 

    Background & Aims. A severe flare-up develops in approximately 15% of patients with ulcerative colitis (UC). It is questionable whether the response to the first parenteral corticosteroid therapy decreases the risk for colectomy. Our aim was to evaluate the association between long-term...

  • Disease Activity, ANCA, and IL23R Genotype Status Determine Early Response to Infliximab in Patients With Ulcerative Colitis. Jürgens, Matthias; Laubender, Rüdiger P; Hartl, Franziska; Weidinger, Maria; Seiderer, Julia; Wagner, Johanna; Wetzke, Martin; Beigel, Florian; Pfennig, Simone; Stallhofer, Johannes; Schnitzler, Fabian; Tillack, Cornelia; Lohse, Peter; Göke, Burkhard; Glas, Jürgen; Ochsenkühn, Thomas; Brand, Stephan // American Journal of Gastroenterology;Aug2010, Vol. 105 Issue 8, p1811 

    OBJECTIVES:We analyzed the efficacy and safety of the antitumor necrosis factor-α antibody infliximab (IFX) for induction therapy in patients with moderate-to-severe ulcerative colitis (UC) in a large single-center cohort.METHODS:A total of 90 UC patients treated with IFX for 14 weeks were...

  • Adrenomedullin Therapy in Patients with Refractory Ulcerative Colitis: A Case Series. Ashizuka, Shinya; Inatsu, Haruhiko; Kita, Toshihiro; Kitamura, Kazuo // Digestive Diseases & Sciences;Mar2016, Vol. 61 Issue 3, p872 

    Background and Aims: Adrenomedullin (AM) is a multifunctional biologically active peptide that has an ameliorative effect against inflammatory bowel disease in several experimental models. We reported the first case where AM infusion dramatically improved symptoms and colonoscopy...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics